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Abstract 
3,4-Methylenedioxymethamphetamine (MDMA) is a psychoactive stimulant abused 
by young people as the recreational drug ecstasy. Other compounds, either 
deliberately added or present as byproducts, are often found in MDMA tablets and can 
unexpectedly interact with each other. The aim of this study was to evaluate the 
pharmacodynamic effects of interactions caused by concomitants in MDMA tablets on 
extracellular dopamine and serotonin (5-HT) by microdialysis in the stiriatum of 
ethylcarbamate-anesthetized rats. 
Baseline levels of dopamine and 5-HT in the striatum were 16.5±7.7 and 3.5±1.7 nM 
(mean ± standard deviation), respectively. After a single administration of MDMA (10 
mg/kg, i.p.), a dramatic increase in extracellular dopamine (Cmax: 36.1-fold vs. 
baseline) and 5-HT levels (Cmax: 9.3-fold vs. baseline) was observed. When rats were 
co-administered with methamphetamine (1, 5 or 10 mg/kg) with MDMA, the 
dopamine levels induced by MDMA increased in a methamphetamine-dose-dependent 
manner (Cmax: 2.5-, 3.5-, and 3.8-fold vs. MDMA). A similar trend was observed in 
5-HT levels (Cmax: 1.1-, 1.3-, and 1.8-fold vs. MDMA). In contrast, ketamine and 
caffeine showed synergistic effects on the monoamine levels induced by MDMA, 
whereas the individual administration of either of these compounds did not affect 
monoamine levels. Ketamine (1, 5 mg/kg) decreased the dopamine levels induced by 
MDMA (Cmax: 0.9- and 0.7-fold vs. MDMA) and increased the 5-HT levels induced by 
MDMA (Cmax: 1.4- and 1.6-fold vs. MDMA), and co-administration of caffeine (20 
2 
mg/kg) with MDMA increased dopamine levels (Cmax: 1.7-fold vs. MDMA). These 
results suggest that exposure to multiple drugs in addition to MDMA can have 
neurotoxic effects. 
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1. Introduction 
3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a designer drug with 
pharmacological and toxicological characteristics similar to amphetamines and 
mescaline as a central nervous system (CNS) stimulant and hallucinogen, respectively 
(Duterte et al., 2009; Kalant, 2001). MDMA was popular with “rave” party 
participants in the early 1990s (Wu et al., 2006). Its present illegal use is spreading 
rapidly among youth in the U.S. (Banken, 2004) and East Asian countries (Ahmad, 
2002) and causes serious social problems. 
MDMA is a potent releaser and/or reuptake inhibitor of presynaptic serotonin (5-HT), 
dopamine, noradrenaline and acetylcholine (Cole and Sumnall, 2003). It is also is a 
substrate for monoamine transporter, and acts as an inhibitor of vesicular monoamine 
transporter and/or monoamine oxidase (Cole and Sumnall, 2003). Intake of MDMA 
results in increased extracellular monoamine levels, and induces intense feelings of 
euphoria, friendliness, comfort, intimacy, pleasure, empathy and hyperactivity (Parrot, 
2001). Its acute physiological effects cause hyperthermia, rhabdomyolysis, acute renal 
failure, cardiac arrest, disseminated intravascular coagulation, liver failure, 
convulsions or cerebral hemorrhage, potentially resulting in death (Capela et al., 
2009; Parrot, 2001). Moreover, long-term MDMA intake results in persistent 
neurotoxicity due to neurodegenerative changes (Escobedo et al., 2005). These 
physiological and psychological effects of MDMA abuse arise from changes in 5-HT 
and dopamine levels, so evaluation of monoamine levels in the brain after MDMA 
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intake might be an important pharmacodynamic parameter for elucidating the 
mechanisms by which MDMA causes neurotoxicity. 
MDMA is commonly prepared as brightly-colored tablets imprinted with a friendly 
logo (Duterte et al., 2009; Makino et al., 2003) and is taken orally. This, and the 
widespread though erroneous belief that “ecstasy is safe”, have promoted the vogue 
for MDMA among youth (Eede et al., 2009; Kalant et al., 2001). Wide variations in 
the concentration of MDMA (1-207 mg/tablet) and the presence of several 
concomitants in seized tablets have been reported (Cole et al., 2002; Duterte et al., 
2009; Makino et al., 2003; Teng et al., 2006; Vogels et al., 2009). For example, abused 
drugs (methamphetamine, amphetamine, ketamine and 
3,4-methylenedioxyamphetamine (MDA)) and/or CNS-effective substances (caffeine, 
ephedrine, and dextromethorphan) have been detected in MDMA tablets. Furthermore, 
the percentage of MDMA tablets containing other substances is increasing 
(Tanner-Smith, 2006). When legal substances which affect the CNS are used as 
concomitants, a stronger stimulant effect may be obtained. Such MDMA tablets would 
therefore be extremely harmful and could result in the user unintentionally abusing 
multiple drugs, leading to enhanced adverse effects or poisoning. 
This investigation aimed to evaluate the acute interaction effects caused by ingestion 
of MDMA tablets by studying dopamine and 5-HT levels in the rat brain after a single 
co-administration of MDMA with methamphetamine, ketamine or caffeine. 
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2. Materials and methods 
2.1 Animals 
Male Wistar rats (7 weeks old, 230-250 g, Kyudo Co. Ltd., Saga, Japan) were 
purchased and housed in plastic cages containing wood chip bedding material under 
standard environmental conditions (ambient temperature 22±1°C, humidity 55±5%, 
and 12 h light-dark cycle) with free access to laboratory diet (MD, Oriental Yeast, 
Tokyo, Japan) and tap water. Animals were used for experiments at 8 weeks of age 
and with weights of 280-320 g, considered to be the rat equivalent of human 
adolescence (Tsuruta et al., 2000). Each group consisted of three rats. All animal 
studies were approved by the Nagasaki University Animal Care and Use Committee. 
 
2.2 Drugs and reagents 
MDMA, a narcotic used for research, was kindly donated by the National Institute of 
Health Sciences (Tokyo, Japan). Methamphetamine hydrochloride (Philopon®) was 
purchased from Dainippon Pharma (Osaka, Japan). Anhydrous caffeine and dopamine 
were purchased from Wako Pure Chemicals (Osaka, Japan). Ketamine (Ketalar® for 
intramuscular injection) was purchased from Daiichi Sankyo (Tokyo, Japan). Sodium 
1-decanesulfonate (SDS) was purchased from Sigma Aldrich Japan (Tokyo), and 
ethylenediamine-N,N,N’,N’-tetraacetic acid disodium salt dihydrate (EDTA·2Na) was 
purchased from Dojindo Laboratories (Kumamoto, Japan). 5-HT was purchased from 
Kanto Chemical (Tokyo, Japan). 
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Dopamine and 5-HT were dissolved in 0.1 M HCl containing 100 mg/l EDTA·2Na to 
prepare 10 mM stock solutions, which were stored in a freezer to avoid decomposition. 
Artificial cerebrospinal fluid (aCSF) prepared with analytical grade reagents 
consisted of KCl 2.5 mM, NaCl 125 mM, MgCl·6H2O 1.0 mM, NaH2PO4·2H2O 0.5 
mM, Na2HPO4·12 H2O 2.5 mM and CaCl2 1.2 mM. 
 
2.3 Experimental design 
MDMA (5, 10, and 20 mg/kg), methamphetamine (1, 5, and 10 mg/kg), ketamine (5, 
10, 20, and 40 mg/kg) or caffeine (20 mg/kg) in 0.9% saline was intraperitoneally 
administered to rats either individually or as combinations of two drugs at 0.1 ml per 
100 g body weight. Saline alone was used for control experiments. For 
co-administration of two drugs, the second drug was administered immediately 
following administration of the first drug. According to interspecies dose scales 
(McCann and Ricaurte, 2001; Mechan et al., 2002), the dose of MDMA used in this 
study (10 mg/kg) is equivalent to a dose of 136 mg in a 70-kg human. Since the 
MDMA content of seized tablets ranges from 1 to 207 mg/tablet (Cole et al., 2002; 
Duterte et al., 2009; Makino et al., 2003; Teng et al., 2006; Vogels et al., 2009), a dose 
of 10 mg/kg is comparable to the ingestion of one or two tablets. 
 
2.4 In vivo brain microdialysis 
Rats were anesthetized with ethylcarbamate (1.5 g/kg, i.p.) and fixed on a stereotaxic 
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system (SR-5R, Narishige Scientific Instrument, Tokyo, Japan). A CMA microdialysis 
system (Carnegie Medicine, Stockholm, Sweden) was used. A MAB6 microdialysis 
probe with a 4-mm, 15-kDa cutoff polyethersulfone membrane (ALS/Microbiotech, 
Stockholm, Sweden) was implanted in the left striatum (coordinates: A, +0.6 mm; L, 
+3.0 mm from bregma; H, -0.7 mm from the skull surface; Paxinos and Watson, 2005) 
and was perfused with aCSF at a flow rate of 2.0 l/min. 
To estimate baseline levels, samples were taken twice at 10-min intervals before drug 
administration, and then baseline samples were collected 60 min after implantation of 
the probe to avoid interference caused by the operation. After drug administration, 
samples were collected every 10 min for 3 h into a sampling tube containing 5 l of 
0.1 M phosphate buffer, and 0.1 M EDTA·2Na, pH 3.5.  
The in vivo recoveries of the dialysis probe (Rin vitro) were calculated from four 
replicate measurements of in vitro recoveries (Rin vitro), in vitro losses (Lin vitro), and in 
vivo losses (Lin vivo), according to previous reports (Sun et al., 2002; Wada et al., 2008). 
For these calculations, aCSF spiked with dopamine (25 nM) and 5-HT (25 nM) was 
used. The relative Rin vitro, Lin vitro and Lin vivo values were calculated to be 8.5%, 96.6% 
and 96.9% for dopamine, and 14.4%, 95.0% and 99.1% for 5-HT, respectively. The 





2.5 HPLC-electrochemical detection 
The dopamine and 5-HT levels in the brain were determined by HPLC using an 
HTEC-500 system (Eicom, Kyoto, Japan) equipped with electrochemical detection. 
Twenty microliters of sample was injected and analytes were separated on an 
Eicompak PP-ODS column (30  4.6 mm, i.d., 2 m, Eicom) using a mixture of 0.1 M 
phosphate buffer (pH 6.0)/methanol (=99:1, v/v) containing 500 mg/l SDS and 50 
mg/l EDTA·2Na. The mobile phase flow rate was 0.5 ml/min and the column 
temperature was set at 25°C. The working electrode was WE-3G (graphite, Eicom) 
and the reference electrode was RE-100 (Ag/AgCl, Eicom). The applied voltage of the 
conditioning cell was set at +400 mV. 
 
2.6 Calculations and statistics 
The dopamine and 5-HT levels in dialysates were calculated from calibration curves 
using the formulas: Y = 5.99·X - 2.43 (for dopamine; Y, peak area (mV·s); X, 
concentration of standard (nM)) and Y = 13.06·X + 4.39 (for 5-HT). The measured 
dopamine and 5-HT concentrations in dialysates were corrected for in vivo recovery, 
and the pharmacokinetic parameters of the amines were obtained with the corrected 
values. 
All data are presented as mean ± standard error of mean (S.E.M., n = 3). The 
dopamine and 5-HT parameters were calculated by moment analysis (Yamaoka et al., 
1978). The peak concentrations (Cmax) and concentration peak times (Tmax) were 
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obtained from the original data. The area under the curve (AUC) for concentration vs. 
time was calculated using the linear trapezoidal rule until 180 min after drug 
administration. The mean residence time (MRT) was calculated from the equation for 
area under the moment curve/AUC. The data for time-concentration profile of MDMA 
with its 10 mg/kg single administration in each figures were same to that in Fig. 1. 
The profiles of dopamine and 5-HT levels vs. time were analyzed by a two-way mixed 
model analysis of variance (ANOVA) with a split plot design followed by Scheffe’s 
post-test. The moment parameters obtained were analyzed by one-way ANOVA 
followed by Scheffe’s post-test, and Student’s t-test was used to compare two groups. 
A P-value less than 0.05 was considered to be statistically significant. Statistical 






3.1 Pharmacodynamic effects of MDMA on dopamine and 5-HT levels in the brain 
The baseline levels of dopamine and 5-HT were 16.5 ± 7.7 nM (n = 48) and 3.5 ± 1.7 
nM (n = 48), respectively. Pre-treatment dopamine levels were relatively high for the 
MDMA 10 mg/kg group, and low for the ketamine 20 mg/kg administered group (P = 
0.016, MDMA 10 mg/kg group vs. ketamine 20 mg/kg group, Scheffe’s post-hoc test). 
No other significant differences in the pre-administration levels of dopamine and 
5-HT among the administered groups were observed. 
The profiles of extracellular dopamine and 5-HT concentrations vs. time after a single 
i.p. administration of saline or MDMA, and the moment parameters, are shown in Fig. 
1 and Table 1, respectively. 
Extracellular dopamine levels were significantly increased by administration of 
MDMA at a dose above 10 mg/kg compared to the saline group (5 mg/kg, P = 0.603; 
10 mg/kg, P = 0.046; 20 mg/kg, P = 0.007; vs. saline group, Scheffe’s post-hoc test). 
The Cmax of dopamine was 23-, 36- and 65-fold compared to the baseline level 
(MDMA 5, 10 and 20 mg/kg, respectively). The AUC also increased dose-dependently 
compared to the saline group (5 mg/kg, P = 0.598; 10 mg/kg, P = 0.047; 20 mg/kg P = 
0.007; vs. saline group, Scheffe’s post-hoc test). 
After MDMA administration, 5-HT levels in the rat striatum significantly increased. 
The AUC increased significantly from low dosage (5 mg/kg, P = 0.003; 10 mg/kg, P = 
0.002; 20 mg/kg, P < 0.001; vs. saline group, Scheffe’s post-hoc test), and it increased 
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non-linearly. In MDMA 20 mg/kg administration group, 5-HT levels were extremely 
increased and the Cmax were 8-, 9- and 23-fold increased from baseline level (MDMA 
5, 10 and 20 mg/kg, respectively).  
Fig. 1, Table 1 
 
3.2 Effect of methamphetamine on the pharmacodynamics of MDMA 
The effects of methamphetamine co-administered with MDMA on extracellular 
dopamine and 5-HT concentrations are shown in Fig. 2 and Table 2. 
Similar to an acute effect of MDMA, the extracellular levels of dopamine and 5-HT 
increased significantly compared to baseline levels after a single administration of 
methamphetmine (10 mg/kg). The Cmax of the dopamine and 5-HT levels were 
increased 84.8- and 14.2-fold over the baseline level.  
Methamphetamine co-administered with MDMA dose-dependently increased the 
extracellular dopamine level compared to the administration of MDMA alone (1 
mg/kg, P = 0.831; 10 mg/kg, P = 0.202, 20 mg/kg, P = 0.091; vs. MDMA 10 mg/kg 
group, Scheffe’s post-hoc test). The Cmax and AUC of MDMA and methamphetamine 
co-administration (2,265.2 ± 157.8 nM and (201.5 ± 14.5) ×103 nM·min in Table 2 for 
MDMA 10 mg/kg + methamphetamine 10 mg/kg) was 4 and 3 times higher than 
MDMA single administration in table 1. However, the amount of dopamine released 
(AUC 201.5×103 nM·min) by the co-administration of MDMA (10 mg/kg) and 
methamphetamine (10 mg/kg) was comparable to the theoretical sum of the amount of 
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dopamine released (AUC 161.8×103 nM·min) calculated by the basal level and each 
drug caused an increase from each sole administration of MDMA or 
methamphetamine alone. 
When rats were co-administered with methamphetamine with MDMA, the Cmax of 
extracellular 5-HT increased in a methamphetamine dose-dependent manner. 
Although the Cmax (MDMA 10 mg/kg + methamphetamine 10 mg/kg: 57.0 ± 13.0 nM, 
Table 2) increased by a factor of two compared to the group administered MDMA 
alone (32.5 ± 4.0 nM, Table 1), the AUC was comparable to that of the group 
administered with methamphetamine alone. 
Fig. 2, Table 2 
 
3.3 Effect of ketamine on the pharmacodynamics of MDMA 
The profiles of extracellular dopamine and 5-HT levels vs. time after each single 
administration of saline, ketamine, MDMA and/or MDMA + ketamine are shown in 
Fig. 3, and the corresponding parameters are given in Table 3. The administration of 
ketamine alone at any dose (5, 10, 20, and 40 mg/kg) did not affect the extracellular 
dopamine and 5-HT levels. 
Co-administration of ketamine tended to dose-dependently decrease extracellular DA 
levels compared to the administration of MDMA alone (5 mg/kg, P = 0.308; 10 mg/kg, 
P = 0.107; ANOVA). However, ketamine increased the Cmax and AUC of 5-HT 
induced by MDMA. Cmax and AUC increased 1.6-fold and 1.8-fold compared to the 
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administration of 10 mg/kg MDMA alone (P = 0.269, P = 0.078; vs. MDMA 10 mg/kg 
group, Scheffe’s post-hoc test). 
When ketamine (20, 40 mg/kg) was co-administered with MDMA, the rats died 10-20 
min after administration, but did not die when ketamine alone was administered. 
Fig. 3, Table 3 
 
3.4 Effect of caffeine on the pharmacodynamics of MDMA 
The profiles of extracellular dopamine and 5-HT levels vs. time for each single 
administration of saline, caffeine, MDMA and/or MDMA + caffeine are shown in Fig. 
4, and the corresponding parameters calculated by moment analysis are shown in 
Table 4. 
Caffeine alone did not have any significant effect on dopamine and 5-HT levels 
compared to the group administered with saline alone. However, caffeine 
co-administered with MDMA significantly shortened the Tmax of dopamine (P = 0.038, 
vs. MDMA 10 mg/kg group, Student’s t-test) and increased dopamine levels in the 
striatum, and the Cmax of dopamine was increased 2-fold compared to the MDMA 
group (P = 0.526, vs. MDMA 10 mg/kg group, Student’s t-test). The Tmax and MRT of 
dopamine were shortened to 25 min (P = 0.184, vs. MDMA 10 mg/kg group, Student’s 
t-test) and 66 min (P = 0.035, vs. MDMA 10 mg/kg group, Student’s t-test) by 
co-administration of caffeine with MDMA. 
Fig. 4, Table 4 
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4. Discussion 
We evaluated the effects of concomitants found in MDMA tablets on brain 
monoamine (dopamine and 5-HT) levels. To our knowledge, this is the first study of 
the pharmacodynamic interactions of MDMA with methamphetamine, ketamine 
and/or caffeine based on the monitoring of dopamine and 5-HT levels in rat striatum. 
Although MDMA produces many adverse effects, hyperthermia is the most lethal. 
Hyperthermia is believed to be caused by multiple factors and to be involved in a 
complex fashion with serotonergic, dopaminergic and adrenergic neuronal functions 
(Capela et al., 2009). MDMA increases dopamine levels in the hypothalamic and other 
thermoregulatory areas (Benamar et al., 2008), and a direct relationship between core 
temperature and long-term loss of 5-HT induced by MDMA has been suggested 
(Goni-Allo et al., 2008). Dopamine and 5-HT are believed to be involved in the 
MDMA-induced acute physiological effect. The striatum is known to be a main target 
of both dopaminergic and serotonergic projections from the midbrain, so monitoring 
dopamine and 5-HT levels in the striatum using microdialysis sampling should be 
useful for assessing the risks caused by MDMA. 
Analysis of seized MDMA tablets revealed the presence of several concomitants 
including methamphetamine, ketamine and caffeine. Methamphetamine is the most 
popular drug of abuse in Japan. Ketamine has an anesthetic pharmacological effect, 
whereas caffeine stimulates the CNS. All three compounds can be present in MDMA 
tablets in very large amounts (methamphetamine, 1-850%; ketamine, 7-74%; and 
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caffeine, 4-113% vs. MDMA content) (Makino et al., 2003; Teng et al., 2006). In this 
study, MDMA acutely increased extracellular dopamine and 5-HT levels compared to 
the saline control group. MDMA directly acts on monoamine transporter (MAT) at 
nerve terminal and could be a substrate for all the presynaptic MATs, including 
serotonin transporter (SERT), dopamine transporter and norepinephrine transporter. 
Of these, SERT has a lower affinity than the norepinephrine transporter, but a higher 
affinity than the dopamine transporter for MDMA, as shown for the rat (Rothman et 
al., 2001) and for the human protein (Pifl et al., 2005; Verrico et al., 2007). In 
addition, MDMA might indirectly affect dopamine levels via 5-HT release (Koch et 
al., 1997). Once 5-HT is released from the striatum, it binds to 5-HT2A/2C receptor, 
thereby attenuating -aminobutylic acid (GABA) mediated feedback control at the 
substantia nigra, leading to dopamine release from the striatum (Yamamoto et al., 
1995). This indirect effect might cause the observed differences in Tmax between 
dopamine and 5-HT. 
5-HT levels were significantly increased by 20 mg/kg administration of MDMA, and 
dopamine levels were increased in a MDMA dose-dependent manner. Several studies 
suggest a non-linear pharmacokinetic response to MDMA in human, monkey and rat 
(Kolbrich et al., 2008; de la Torre et al., 2000; Chu et al., 1996; Mueller et al., 2008). 
Consistent with this, MDMA overdosing (20 mg/kg) caused extreme enhancement of 
dopamine and 5-HT release in the current study, suggesting that the deleterious effects 
of MDMA overdosing are particularly focused on the brain neurological effects of 
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extracellular dopamine and 5-HT. 
Once MDMA enters nerve terminal through SERT or by diffusion, it acts as 1) an 
enhancer of 5-HT release from storage vesicles, 2) an inhibitor of tryptophan 
hydroxylase, a 5-HT synthesis enzyme, and 3) an inhibitor of monoamine oxidase B 
(MAO-B), a 5-HT degradation enzyme; moreover, it acts as 4) an agonist to the 
5-HT2A receptor at the synapse (Capela et al., 2009).  
There have been a few reports regarding the physical or pharmacological effects 
resulting from interactions caused by MDMA tablet intake or multi-drug abuse. 
Kuwayama et al. (2007) reported the effects of MDMA, ketamine and caffeine 
interactions on intestinal absorption by Caco-2 cells and suggested that a common 
transport system for MDMA, methamphetamine, ketamine and caffeine affects 
MDMA absorption. The effects of a combination of MDMA and methamphetamine on 
anxiety behavior and neurochemistry (monoamines measured following brain 
dissection) following a single administration (Clemens et al., 2004) and long-term 
administration (four times, Clemens et al., 2005; 10 weeks, Clemens et al., 2007) 
were reported and showed that drugs used in combination enhanced the adverse 
effects of a drug used alone. Ke et al. (2008) reported that the administration of 
ketamine 12 h before the administration of MDMA aggravated MDMA-induced 
dopaminergic toxicity, determined by measuring monoamine levels in brain dissection 
samples. Caffeine co-administrated with MDMA induced tachycardia (McNakamura 
et al., 2007); furthermore, caffeine promotes MDMA-induced toxicity such as 
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hyperthermia and increased 5-HT levels in brain tissue (McNakamura et al., 2006) 
and 5-HT2 receptor down regulation (Camarasa et al., 2006). In a previous study, we 
investigated the pharmacokinetic interactions of MDMA with caffeine in rat brain and 
blood and found that caffeine decreased MDMA levels and prolonged MRT of MDMA 
in the brain (Tomita et al., 2007). 
In this study, co-administration of methamphetamine enhanced the release of 
dopamine induced by MDMA, but did not affect the release of 5-HT significantly. 
Ketamine suppressed extracellular dopamine release induced by MDMA and 
accelerated 5-HT release, while ketamine alone had no effect on dopamine and 5-HT 
release. On the other hand, caffeine co-administration increased the dopamine levels 
and shortened the Tmax of the dopamine levels, whereas caffeine alone had no effect on 
dopamine and 5-HT levels. These results suggest that methamphetamine, ketamine 
and caffeine might enhance the toxicity of MDMA. 
Methamphetamine stimulates the CNS, and methamphetamine-induced neurotoxicity 
damages the striatal dopaminergic and serotonergic nerve terminal. Methamphetamine 
is a substrate for MAT and can more potently affect DAT than SERT (Rothman et al., 
2001; Baumann et al., 2007). Co-administration of methamphetamine with MDMA 
caused additive dopamine release at the striatum in rats, indicating that each drug 
might independently diffuse into the brain and affect dopamine levels in neurons. On 
the other hand, extracellular 5-HT levels are believed to attain threshold levels by the 
administration of MDMA alone. Therefore, methamphetamine might not affect 
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MDMA-induced 5-HT levels additively. However, Clemens et al. (2004) reported that 
a combination of MDMA and methamphetamine enhanced dopamine and 5-HT 
depletion; therefore, the long-term effects and acute effects of methamphetamine may 
be different.  
Ketamine is a noncompetitive antagonist of N-methyl-D-aspartate receptor, and has 
been used for anesthesia in animals. Verma and Moghaddam (1996) reported that 
ketamine increased dopamine release at the prefrontal cortex, but not at the striatum. 
These results are compatible with our results, in which ketamine alone did not affect 
dopamine and 5-HT levels in the rat striatum under ethyl carbamate anesthesia. On the 
other hand, our results showed that co-administration of ketamine produced the 
opposite effect on dopamine and 5-HT: ketamine decreased dopamine release induced 
by MDMA, but enhanced 5-HT release. This might be due to acute toxicity. However 
the effect of ketamine on monoamine decomposition involving monoamine oxidase or 
catechol O-methyltransferase remains unclear. 
Caffeine, a psychoactive substance, is a nonselective adenosine receptor antagonist. 
Caffeine antagonizes adenosine A2A receptor, which is thought to regulate dopamine 
signaling (Singh et al., 2009). In this study, caffeine had a synergistic effect on 
dopamine release induced by MDMA. Pharmacokinetic interactions should be also 
taken into consideration when drugs are co-administered. Amphetamine, an active 
metabolite of methamphetamine, is a substrate for CYP2D6 (Sweeney and Bromilow, 
2006), as is MDMA. MDMA is metabolized through N-demethylation and 
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O-demethylation processes. MDMA is mainly N-demethylated by CYP1A2 in rodents, 
and caffeine is also metabolized by the same enzyme (Singh et al., 2009). Thus, 
competitive interactions between MDMA and caffeine for CYP should be considered. 
Tomita et al. (2007) reported that the Tmax and MRT of MDMA (5 mg/kg, i.p.) in the 
brain were considerably prolonged by the co-administration of caffeine (20 mg/kg, 
i.p.) and that Cmax was drastically decreased, while the Cmax of MDMA in blood was 
not affected. Therefore, caffeine might affect the pharmacokinetics to the brain 
towards MDMA. 
In addition to interactions involved with neurotoxicity, the physiological effects of 
MDMA have also been examined. Caffeine produced unexpected hyperthermia and 
tachycardia (McNakamura et al., 2006, 2007) when co-administered with MDMA. In 
our study, co-administration of ketamine (20 and 40 mg/kg) with MDMA was lethal, 
while the administration of ketamine or MDMA alone was not. These results show 
that the co-administration of ketamine not only has neurological effects, but also 
enhances the systemic physical toxicity of MDMA. 
Increases in MDMA-induced dopamine and 5-HT release, and the neurotoxicity of 
5-HT by MDMA, suggest the involvement of MDMA metabolites (Escobedo et al., 
2005; Erives et al., 2008; Colad et al., 2004) and the formation of reactive oxygen 
species (Erives et al., 2008; Gudelsky and Yamamoto, 2008; Quinton and Yamamoto, 
2006). Clarification of the mechanism of drug interactions with MDMA, especially 
with respect to metabolism and the formation of reactive oxygen species, will require 
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further study. 
This study was performed in ethyl carbamate anesthetized rat. Some researches 
showed that ethyl carbamate would inhibit CYP3A and increase CYP 1E and 1A 
activity in rat (Loch et al., 1995; Meneguz et al., 1999). However, influence of 
extracellular dopamine in rat striatum by volatile anesthetic, halothane has been 
reported (Adachi et al., 2001), therefore, ethyl carbamate was selected. Further study 
in freely-moving microdialysis is needed to elucidate physiological effect by the 
interactions.  
In conclusion, co-administration of methamphetamine, ketamine and caffeine with 
MDMA seriously affected MDMA-induced dopamine and 5-HT release in the rat 
striatum, indicating the potential risks associated with MDMA abuse. 
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Fig. 1 Time-concentration profiles of extracellular dopamine (A) or 5-HT (B) after a 
single administration of saline or MDMA (5, 10, and 20 mg/kg, i.p.) as determined by 
microdialysis in ethylcarbamate-anesthetized rats. 
Data represent the mean + S.E.M. (n = 3). P-values were calculated by two-way mix 
mode ANOVA with Scheffe’s post-hoc test for the saline group and the three 




Fig. 2 Time-concentration profiles of extracellular dopamine (A) or 5-HT (B) after a 
single administration of MDMA (10 mg/kg, i.p., Fig. 1), methamphetamine (10 mg/kg, 
i.p.) or MDMA (10 mg/kg, i.p.) + methamphetamine (10 mg/kg, i.p.) as determined by 
microdialysis in ethylcarbamate-anesthetized rats. 
Data represent the mean + S.E.M. (n = 3). P-values were calculated by two-way mix 
mode ANOVA with Scheffe’s post-hoc test. ** P < 0.01, * P < 0.05 vs. saline group; †† 




Fig. 3 Time-concentration profiles of extracellular dopamine (A) or 5-HT (B) after a 
single administration of saline, ketamine (10 mg/kg, i.p.), MDMA (10 mg/kg, i.p.) or 
MDMA (10 mg/kg, i.p.) + ketamine (10 mg/kg, i.p.) as determined by microdialysis in 
ethylcarbamate-anesthetized rats. 
Data represent the mean + S.E.M. (n = 3). P-values were calculated by two-way mix 
mode ANOVA with Scheffe’s post-hoc test. ** P < 0.01 vs. saline group; †† P < 0.01, † 




Fig. 4 Time-concentration profiles of the dopamine (A) or 5-HT (B) response after a 
single administration of saline, caffeine (20 mg/kg, i.p.), MDMA (10 mg/kg, i.p.) or 
MDMA (10 mg/kg, i.p.) + caffeine (20 mg/kg, i.p.) as determined by microdialysis in 
ethylcarbamate-anesthetized rats.  
Data represent the mean + S.E.M. (n = 3). P-values were calculated by two-way mix 
mode ANOVA with Scheffe’s post-hoc test. ** P < 0.01 vs. saline group; †† P < 0.01 
MDMA 10 mg/kg group; and ¶¶ P < 0.01 vs. caffeine group.
Table 1 Moment parameters of dopamine and 5-HT levels after single administration 
of MDMA (5, 10, 20 mg/kg, i.p.). 
 Saline a MDMA P 
 5 mg/kg a 10 mg/kg b 20 mg/kg a 
dopamine      
















± 12.2 d 
83.8 
± 18.9 e 
0.004 f 
MRT (min) (84 ± 3) 79 ± 9 82 ± 5 70 ± 5 0.495 c 
5-HT      
Cmax (nM) − 26.9 ± 5.9 32.5 ± 4.0 82.0 ± 10.4 0.003 
c 







± 0.2 e 
2.0 
± 0.1 e 
5.8 
± 0.3 e 
<0.001 f
MRT (min) (72 ± 2) 63 ± 3 61 ± 3 64 ± 7 0.833 c 
Data were represented as mean ± S.E.M. 
a Administration of saline or MDMA (5 and 20 mg/kg) to rats (n = 3). 
b Simultaneous administration of MDMA (10 mg/kg) and saline to rats (n = 3). 
c P-values were calculated by one-way ANOVA of three MDMA groups (5, 10, and 20 
mg/kg). 
d P < 0.05, vs. saline group (Scheffe’s post-hoc test). 
e P < 0.01, vs. saline group (Scheffe’s post-hoc test). 
f P-values were calculated by one-way ANOVA of saline and MDMA groups (5, 10, 
and 20 mg/kg). 
 
Table 2 Moment parameters of dopamine and 5-HT levels after single administration 
of methamphetamine and co-administration of MDMA with methamphetamine. 
MDMA − 10 mg/kg 10 mg/kg 10 mg/kg P 
methamphetamine 10 mg/kg a 1 mg/kg b 5 mg/kg b 10 mg/kg b 
dopamine      






















MRT (min) 68 ± 1 67 ± 2 76 ± 5 76 ± 4 0.041 d 
5-HT    
Cmax (nM) 49.7 ± 11.2 36.9 ± 5.8 41.3 ± 8.9 57.0 ± 13.0 0.388
c 













MRT (min) 56 ± 1 58 ± 2 65 ± 4 60 ± 3 0.024 d 
Data were represented as mean ± S.E.M. 
a Administration of methamphetamine (10 mg/kg) to rats (n = 3). 
b Simultaneous administrations of MDMA (10 mg/kg) and methamphetamine (1, 5 or 
10 mg/kg) to rats (n = 3, respectively). 
c P-values were calculated by one-way ANOVA of methamphetamine (10 mg/kg), 
MDMA (10 mg/kg, Table 1), MDMA (10 mg/kg) + methamphetamine (1, 5, 10 mg/kg) 
groups. 
d P-values were calculated by one-way ANOVA of saline, methamphetamine (10 
mg/kg), MDMA (10 mg/kg, Table 1), MDMA (10 mg/kg) + methamphetamine (1, 5, 
10 mg/kg) groups. 
e P < 0.05, vs saline group (Scheffe’s post-hoc test). 
f P < 0.05, g P < 0.01, vs MDMA (10 mg/kg, Table 1) sole-administration group 
(Scheffe’s post-hoc test). 
 
Table 3 Moment parameters of dopamine and 5-HT levels after single administration 
of ketamine and co-administration of MDMA and ketamine. 
MDMA (mg/kg) − − − − 10 10 P 
Ketamine 
(mg/kg) 
5 a 10 a 20 a 40 a 5 b 10 b 
dopamine        

























MRT (min) (79 ± 2) (82 ± 3) (76 ± 3) (81 ± 4) 60 ± 7 59 ± 6 0.062 c 
5-HT        






















MRT (min) (73 ± 10) (70 ± 2) (70 ± 2) (67 ± 6) 58 ± 4 61 ± 2 0.749 c 
Data were represented as mean ± S.E.M. 
a Simultaneous administration of saline and ketamine (5, 10, 20, 40 mg/kg) to rats (n 
= 3, respectively). 
b Simultaneous administration of MDMA (10 mg/kg) and ketamine (5 or 10 mg/kg) to 
rats (n = 3, respectively). 
c P-values were calculated by one-way ANOVA of MDMA (10 mg/kg, Table 1) and 
MDMA (10 mg/kg) + ketamine (5, 10 mg/kg) groups. 
d P-values were calculated by one-way ANOVA of saline, ketamine (5, 10, 20, 40 
mg/kg), MDMA (10 mg/kg, Table 1), MDMA (10 mg/kg) + ketamine (5, 10 mg/kg) 
groups. 
e P < 0.01 vs saline group (Scheffe’s post-hoc test). 
f P < 0.05, g P < 0.01, vs MDMA (10 mg/kg, Table 1) sole-administration group 
(Scheffe’s post-hoc test). 
 
Table 4 Moment parameters of dopamine and 5-HT levels after single administration 
of MDMA or caffeine and co-administration of MDMA and caffeine. 
MDMA − 10 mg/kg P 
Caffeine 20 mg/kg a 20 mg/kg b 
dopamine    
Cmax (nM) − 1,017.3 ± 92.1 0.076
c 
Tmax (min) − 25
f ± 0 0.038 c 
AUC (×103 nM·min) 1.7 g ± 0.6 72.5 e ± 10.8 <0.001 d 
MRT (min) (85 ± 4) 63 f ± 3 0.035 c 
5-HT    
Cmax (nM) − 28.8 ± 3.5 0.526
c 
Tmax (min) − 25 ± 0 0.184
c
AUC (×103 nM·min) 0.4 g ± 0.2 2.3 e ± 0.1 <0.001 d 
MRT (min) (79 ± 5) 66 ± 4 0.406 c 
Data were represented as mean ± S.E.M. 
a Simultaneous administration of saline and caffeine (20 mg/kg) to rats (n = 3). 
b Simultaneous administration of MDMA (10 mg/kg) and caffeine (20 mg/kg) to rats 
(n = 3). 
c P-values were calculated by Student’s t-test comparing to MDMA (10 mg/kg, Table 
1) group and MDMA (10 mg/kg) + caffeine (20 mg/kg). 
d P-values were calculated by one-way ANOVA of saline, caffeine (20 mg/kg), 
MDMA (10 mg/kg, Table 1) and MDMA (10 mg/kg) + caffeine (20 mg/kg) groups. 
e P < 0.01, vs saline group (Scheffe’s post-hoc test). 
f P < 0.05, g P < 0.01, vs MDMA (10 mg/kg, Table 1) sole-administration group 
(Scheffe’s post-hoc test) 
 
